Meclicure SR Tablet is a sustained-release formulation combining Meclizine 50 mg and Folic Acid 5 mg, designed to provide effective management of vertigo, motion sickness, and associated nausea while supporting hematological health. Meclizine, an antihistamine with anticholinergic properties, acts centrally to reduce vestibular stimulation and suppress the vomiting reflex, thereby alleviating symptoms of dizziness and nausea commonly encountered in vestibular disorders. The sustained-release mechanism ensures prolonged therapeutic plasma levels, enhancing patient compliance and symptom control. Folic Acid, a vital B-vitamin, plays a crucial role in DNA synthesis, red blood cell formation, and neurological function, making its inclusion beneficial in preventing folate deficiency anemia and supporting overall neural health, particularly in populations at risk such as pregnant women or those with malabsorption syndromes. Meclicure SR is indicated for the treatment and prevention of motion sickness, vertigo associated with vestibular dysfunction, and folate deficiency states. It should be used under medical supervision, with caution advised in patients with hypersensitivity to antihistamines, glaucoma, or prostatic hypertrophy. Common side effects may include drowsiness, dry mouth, and gastrointestinal disturbances. Meclicure SR offers a dual therapeutic approach, addressing both vestibular symptoms and nutritional requirements in a convenient once-daily regimen.